The ambition of the MRGM is to decipher the molecular mechanisms laying at the root of the pathophysiology of rare diseases and make our findings worth for patients.
Research at MRGM (INSERM U1211) lays on 2 branches:
-
In the Genetic anomalies of Development axe, we are identifying and characterizing candidate genes that are linked to various rare diseases including albinism, Oculo-Auriculo-Vertebral Spectrum (OAVS), Rubinstein-Taybi syndrome, and pathologies associated to RAS dysfunction.
-
In the innate errors of mitochondrial metabolism axe, we are investigating how mitochondrial bioenergetics and dynamics govern fundamental cellular functions involved in rare diseases, cancer and immune responses. One part is more physiopathological: genetic and biochemical alterations of altered metabolic pathways. The other part is more fundamental: analysis of the biochemical pathways of energy and lipid metabolism.
The MRGM closely intertwines with patient associations and the University of Bordeaux to anchor in the society. Together with the Genetic Department of the Public Hospital of Bordeaux, the MRGM is part of the French Centers of References for Developmental Anomalies (SOOR), Neurogenetic Diseases (NEUROGENE), and Mitochondrial Diseases (CARAMMEL and Wolfram syndrome), thereby contributing in improving public health system and patient care.
Our aim is to improve diagnosis, reveal new targets, and develop new drugs for the treatment of rare diseases.
We are on LinkedIn
MRGM leaves X. Follow us on Linkedin.
https://www.linkedin.com/company/mrgm-france/mycompany/?viewAsMember=true
Today marked the kick-off meeting of the ANKIAL Pharma – ERDERA collaborative project, dedicated to advancing mitochondrial anti-hypertrophy therapy for selected rare diseases including Costello and Noonan syndromes.We are grateful for ERDERA’s support, which is instrumental in fostering this ambitious international collaboration and increasing the visibility of research aimed at developing innovative treatments for patients…
Congratulations to Alice REFEYTON, Marija Vlaski-Lafarge and the EFS research team in Bordeaux directed by Zoran Ivanovic, part of MRGM : Maladies Rares Génétiques et Métabolisme laboratory Inserm U1211. An original alternative pathway for OXPHOS fueling is discovered in this work with implications for human stem cells therapy. Great collaboration with Milos Filipovic team. Département…
COLLOQUE « RECHERCHE & MALADIES RARES »
Pessac (Bordeaux). Dr Julien Van Gils. Identification de biomarqueurs pour le diagnostic dusyndrome de Rubinstein-Taybi. Plus d’information : symdrome Rubinstein-Taby
Rare Diseases: Genetics and Metabolism 